Results 31 to 40 of about 2,479 (207)

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials

Frontiers in Neurology, 2020
Background: Fremanezumab (TEV-48125) is a fully-humanized immunoglobulin G isotype 2a selective monoclonal antibody that potently binds to calcitonin gene-related peptide (CGRP).
Bixi Gao, Nan Sun, Yanbo Yang, Yue Sun, Mingjia Chen, Zhouqing Chen, Zhong Wang   +6 more
doaj   +1 more source

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

The Journal of Headache and Pain, 2022
Background Migraine is the second leading cause of disability worldwide. Although many preventive treatments reduce migraine frequency and severity, it is unclear whether these treatments reduce migraine-related disability in a clinically meaningful way.
Peter McAllister, Joshua M. Cohen, Verena Ramirez Campos, Xiaoping Ning, Lindsay Janka, Steve Barash   +5 more
doaj   +1 more source

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies [PDF]

, 2021
Background Migraine preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs) has a positive effect on patients' health-related quality of life (HRQoL).
Mecklenburg, Jasper, Neeb, Lars, Overeem, Lucas Hendrik, Raffaelli, Bianca, Reuter, Uwe, Siebert, Anke, Steinicke, Maureen, Terhart, Maria   +7 more
core   +1 more source

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study

BMC Neurology, 2023
Background There have been very few real-world studies reported in the literature solely focusing on fremanezumab in Asia. This study aimed to evaluate the efficacy and safety of fremanezumab in a real-world setting in Japan. Method This single-centered,
Seiya Ohtani, Narumi Watanabe, Keiko Ihara, Nobuyuki Takahashi, Naoki Miyazaki, Kei Ishizuchi, Ryo Takemura, Satoko Hori, Jin Nakahara, Tsubasa Takizawa   +9 more
doaj   +1 more source

11th European Headache Federation Congress jointly with 31st Congress of the Italian Society for the Study of Headaches : Rome, Italy. 01-03 December 2017 [PDF]

, 2017
. Aims of the study were explore the relationship between peripheral chromatic and central visual dysfunction evaluating also the presence of functional receptor impairment in patients with migraine, with and without aura examined ...
Brighina, F, Catalano, E, Cillino, S, Cosentino, G, Fierro, B, Firpo, V   +5 more
core   +1 more source

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Neurology and Therapy, 2023
Introduction Chronic migraine (CM) patients commonly take acute headache medications, often resulting in medication overuse (MO). This post hoc analysis evaluated the efficacy of fremanezumab in CM patients from Japan with and without MO, which is not ...
Noboru Imai, Yuki Isogai, Yoshiyuki Shibasaki, Masami Nakai, Miki Ishida, Xiaoping Ning, Nobuyuki Koga   +6 more
doaj   +1 more source

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

The Journal of Headache and Pain, 2022
Background The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, have been ...
Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari   +10 more
doaj   +1 more source

Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients

The Journal of Headache and Pain, 2022
Background Early onset of action has become recognized as an important efficacy feature of preventive migraine treatment, which can help overcome adherence issues commonly associated with older medications.
Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, Miki Ishida, Byung-Kun Kim, Xiaoping Ning, Nobuyuki Koga   +6 more
doaj   +1 more source

Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario [PDF]

, 2023
Objectives: Migraine is a neurological disease with a high frequency of incidence. The new monoclonal antibodies selective for the calcitonin gene-related peptide and its ligand (anti-CGRP mAbs) have been marketed both in the USA and EU based on the ...
Ferrara, Francesco, Langella, Roberto, Lasala, Ruggero, Musazzi, Umberto Maria, Sabbatucci, Michela, Vitiello, Antonio, Zovi, Andrea   +6 more
core   +1 more source

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

The Journal of Headache and Pain, 2022
Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs).
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo FilippiBonassi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, for the FRIEND-Study Group   +14 more
doaj   +1 more source